Other languages Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Delayed Nasdaq Other stock markets 12:10:25 2024-04-29 EDT			5-day change	1st Jan Change
2.85 ^USD	-8.06%		-13.64%	-10.97%

03-26	Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-15	Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	03-15
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research	02-07
Virpax Pharmaceuticals Stockholders Approve Reverse Stock Split Plan; Shares Fall	12-29
Virpax Pharmaceuticals Announces Leadership Transition	11-17
Virpax Pharmaceuticals, Inc. Announces CEO Changes	11-16
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16
Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review	23-10-31
Virpax Names Gerald Bruce as CEO of Novvae Pharmaceuticals Unit	23-10-02
Novvae Pharmaceuticals Announces Executive Appointments	23-10-02
Altasciences von Virpax ausgewählt, um die Entwicklung eines neuen Medikaments zur Verhinderung der Ausbreitung von grippeähnlichen Viren zu unterstützen	23-09-21
Altasciences choisi par Virpax pour soutenir le développement d'un nouveau médicament pour empêcher la propagation de virus apparentés à la grippe	23-09-21
Virpax Pharmaceuticals, Inc Announces the Formation of Novvae? Pharmaceuticals	23-09-18
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method	23-08-10
Virpax Pharmaceuticals Files Patent For Envelta Product Candidate	23-07-13
Top Premarket Gainers	23-06-28
Virpax Pharmaceuticals Names New CFO	23-06-20
Virpax Pharmaceuticals, Inc. Announces Executive Changes	23-06-20
Virpax Pharmaceuticals, Inc. Appoints Barbara Ruskin as Class I Director	23-06-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Other languages

Filters